Pharmidex provides both in vitro and preclinical solutions in the treatment of autoimmune diseases such as multiple sclerosis, psoriasis, atopic dermatitis, alopecia and vitiligo.

Our extensive expertise in this field can combine proof of concept studies with pharmacokinetic, pharmacodynamics, toxicological and bioanalytical endpoints to help fast track your research programmes.

Areas of Expertise

Alopecia

Cyclophosphamide, cisplatin, fluorouracil

• Maximum study duration: 2 months
• Routes of administration: Topical, oral, intraperitoneal and subcutaneous
• Various species 

Psoriasis

Imiquimod model

• Maximum study duration: 3 weeks
• Routes of administration: Topical, oral, intraperitoneal, intranasal, intravenous and subcutaneous
• Various species

Immune response elicited by allergens, antigens or cells

Adaptive cell transfer

Atopic Dermatitis

Haptens, OVA and HDM model

• Maximum study duration: 3 months.
• Routes of administration: Topical, oral, intraperitoneal, intravenous and subcutaneous
• Various species

Vitiligo

Monobenzene

• Maximum study duration: 13 weeks
• Routes of administration: Topical
• Single species

Multiple Sclerosis (EAE)

MOG35-55 peptide and proteolipid protein

• Drug treatment observation period: 40 days. 
• Maximum study duration: 3 months
• Routes of Administration: Oral, intraperitoneal, intranasal, intravenous, intrathecal and subcutaneous
• Various species

Colitis

Chemically induced IBD

• IBD induced by compounds such as dextran sulfate sodium (DSS), 2,4,6-trinitrobenzene sulfonic acid (TNBS)
• Can be administered orally (AA) or in drinking bottles (AA) or intra rectally (AB).